Solutions for EMT and Tumor Invasion and Metastasis
Relying on the technology platform of the tumor microenvironment center, Alfa Cytology offers a comprehensive solution for investigating the specific mechanisms of epithelial mesenchymal transition (EMT) action in tumor invasion / metastasis to help researchers successfully achieve their research goals.
Introduction
Epithelial-mesenchymal transitions (EMT) are processes by which polar epithelial cells are transformed into motile mesenchymal cells that acquire the ability to invade and migrate, and are present in several physiological and pathological processes in the human body. Current experimental studies have demonstrated that EMT plays an important role in infiltrative metastasis in tumors of epithelial origin such as oral cancer, breast cancer, ovarian cancer, lung cancer, prostate cancer, liver cancer, pancreatic cancer and rectocolorectal cancer. During tumorigenesis, normal epithelial cells undergo EMT and progress to become carcinoma in situ, after which the tumor cells continue to develop and can invade and spread in situ through epithelial mesenchymal transition (EMT), invade lymphatic vessels and blood vessels and metastasize distantly. The process of EMT is accompanied by down-regulation of epithelial cell markers such as E-calmodulin (E-cad) and β-cadherin and up-regulation of mesenchymal phenotypic markers such as vimentin and N-cadherin (N-cad). It has also been shown that EMT promotes tumor metastasis and allows cells to escape apoptosis (HGF, EGF, FGF, TGF-B).
Solutions
Although, great progress has been made in the understanding of EMT, due to the heterogeneity of tumors, individual differences and the complexity of EMT regulation, the detailed regulatory mechanism of EMT and its role in tumorigenesis and development still need to be further elucidated. Therefore, further in-depth studies on the regulatory mechanisms of EMT and its role in tumor invasion and metastasis are important for better tumor prevention and treatment and the development of new anti-tumor drugs. Alfa Cytology has established an innovative tumor microenvironment center technology platform and is developing several technologies that aims to help customers study how tumor microenvironment (TME) affects epithelial mesenchymal transition (EMT) and the role of EMT in tumor invasion, migration and metastasis, and elucidate its molecular mechanism, providing theoretical guidance for the evaluation and development of the effect of anti-tumor drugs.
Key technologies
In vitro experiments on cell migration, cell-cell interactions and other cellular life activities will be able to reveal the intrinsic laws of tumor development and other biological phenomena. This requires in vitro experiments to better mimic the in vivo environment, so that the research results are closer to the in vivo reality. In vivo tumor animal models are the best choice, which can well simulate the in vivo development of tumors with fewer influencing factors. Combined cellular in vitro experiments and tumor animal models to study cellular changes during interstitial transformation and changes in the in vivo environment can meet the conditions. This is all the more convenient for us to study how the tumor microenvironment (TME) affects epithelial mesenchymal transition (EMT) and the molecular mechanisms involved in the process of EMT promoting tumor invasion, migration and metastasis.
Alfa Cytology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.